Psychiatry Investig Search


Psychiatry Investig > Volume 20(10); 2023 > Article
Huang, Du, Pu, Shi, Xiao, Chen, Yao, Wang, Li, Xue, and Cui: Association Between Metabolic Risk Factors and Cognitive Impairment in Schizophrenia Based on Sex



Sex differences have been observed in many aspects of schizophrenia, including cognitive deficits. Despite extensive research into the relationship between metabolic factors and cognitive deficits in schizophrenia, few studies have explored the potential sex difference in their association.


We recruited 358 schizophrenia patients and 231 healthy controls. The participants underwent measurements of body mass index (BMI), waist circumference, blood pressure, triglycerides, high-density lipoprotein cholesterol, and fasting blood glucose. Metabolic risk factors included abdominal obesity, hypertension, hyperglycemia, and dyslipidemia. A collection of these metabolic risk factors has been defined as metabolic syndrome. These diagnoses were based on the criteria of the National Cholesterol Education Program’s Adult Treatment Panel III. Cognitive performance was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A descriptive analysis, difference analysis, and linear regression model were used to identify the metabolic risk factors for cognitive function in schizophrenia.


Our findings revealed sex differences in the rate of abdominal obesity and hypertension in schizophrenic patients. Additionally, we observed sex differences in the association between metabolic risk factors and cognitive impairment in schizophrenia. Specifically, hyperglycemia was associated with the immediate memory index score of RBANS in male patients, while dyslipidemia was associated with language, attention, delayed memory index scores, and RBANS total score in female patients.


Our results suggest that sex should be considered when evaluating the impact of metabolic disorders on the cognitive function of schizophrenic patients. Moreover, our study identifies hyperglycemia and dyslipidemia as potential targets for precise treatment by sex stratification, which could benefit the improvement of cognitive impairment in schizophrenic patients.


Schizophrenia is a severe psychiatric disorder characterized by positive symptoms, negative symptoms, and cognitive deficits. It affects approximately 1% of the world’s population and ranks as one of the top 10 global causes of disability [1]. Cognitive impairment is one of the core features of schizophrenia, involving a series of impaired neurocognitive functions. This impairment is critically associated with patients’ recovery of social functions and long-term outcomes, while pharmaceutical therapy and psychosocial interventions have limited effects on its improvement [2,3]. Therefore, it is crucial to have a deep understanding of the related risk factors of cognitive impairment in schizophrenia.
Studies in the general population have indicated that several metabolic factors are associated with cognitive impairment and dementia, including diabetes or increased fasting plasma glucose concentrations, abdominal obesity, hypertension, and dyslipidemia [4,5]. A cluster of these metabolic risk factors has been termed metabolic syndrome (MetS) [6,7]. In schizophrenic patients, the prevalences of metabolic risk factors are significantly higher than in the general population [8]. The high prevalence may be due to the pathology of the disease and the side effects of antipsychotic treatment [8]. The relationship between metabolic risk factors and neurocognitive deficits has also been investigated in schizophrenia, and available studies suggest that the occurrence of metabolic risk factors and MetS can worsen existing cognitive impairment in schizophrenia [9-12]. A meta-analysis published in 2021, including 10,174 schizophrenic patients, indicated that the presence of metabolic risk factors and MetS are significantly associated with cognitive deficits in patients [13]. These findings suggest that improving metabolic risk factors and MetS may help manage cognitive impairment in schizophrenia.
Notably, in the general population, researchers have found that the association between metabolic risk factors and cognitive function is affected by sex [14-16]. For example, Huo et al. [16] found that specific risk factors (diabetes and dyslipidemia) have stronger associations with cognitive decline for women than men. Schuur et al. [15] reported that MetS was associated with poorer executive function only in women. Sex differences have been found in many aspects of schizophrenia, such as disease incidence, age of onset, clinical symptoms, response to treatment, long-term outcome, and social functions [2,17]. Male patients have an earlier age of onset, more severe negative symptoms, and worse long-term disease outcomes [17,18]. Studies also suggest sex differences in brain morphology and cognitive function in schizophrenia. For instance, neuroanatomical studies have found that the morphological abnormalities of the brain are more evident in male patients than in female patients [17]. Studies also found that male patients experience more cognitive impairments than female patients, especially in verbal learning and memory tasks [19,20]. Although several studies have explored the relationship between metabolic risk factors and cognitive function in schizophrenia, few studies have investigated the impact of sex on their association.
Taken together, these findings prompt us to raise the question of whether sex affects the association between metabolic risk factors and cognitive function in schizophrenia patients. If so, it could help us to tailor the treatment of metabolic risk factors by sex stratification in patients, resulting in better improvement of their cognitive deficits. Therefore, the primary purpose of this study is to investigate the association of metabolic risk factors with cognitive deficits in schizophrenic patients based on sex. The secondary purpose is to investigate the impact of sex on cognitive deficits and the rate of metabolic risk factors in schizophrenic patients.



All participants recruited were Han Chinese and aged between 18 and 65 years. Patients were recruited from Shanghai Mental Health Center, Shanghai Civil Affairs First Mental Health Center, Cixi Mental Health Center, Quzhou Third People’s Hospital, and Huzhou Third People’s Hospital between January 2017 and January 2020. All patients who met the diagnosis of schizophrenia were included, and the diagnosis was made by experienced psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Patients with any other major Axis I disorder, such as mental disorders due to a general medical condition, delirium, dementia, amnestic and other cognitive disorders, mood disorders, acute stress disorder, and schizoaffective disorders, were excluded. We have excluded the patients with comorbidity of depressive disorders. Because depressive disorder is highly correlated to cognitive function and more common in women, which can affect the interpretation of results. Healthy controls were recruited from the local community through advertisements. Both patients and healthy controls were interviewed by trained raters using the Mini-International Neuropsychiatric Interview to confirm the clinical diagnosis of schizophrenia or to screen whether the controls have any major Axis I disorder diagnosis. Healthy controls with a personal or family history of psychiatric disorders were excluded. Furthermore, participants with cerebral vascular disease, central nervous system diseases, severe physical diseases, substance abuse/dependence, pregnancy, or lactation were also excluded. Finally, 358 schizophrenic patients (244 males and 114 females) and 231 healthy controls (111 males and 120 females) were included in the statistical analysis.
The protocol was reviewed and approved by the Ethics Committee at Shanghai Mental Health Center (IRB No. 2019-35R). Written informed consent was obtained from all subjects before the study.

Clinical assessment and cognitive evaluation

Sociodemographic information and clinical characteristics, such as sex, age, education, height, weight, age of onset, duration of illness, antipsychotics use, and other medications, were collected using the self-designed questionnaire. Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) [21]. The inter-rater correlation coefficient for assessments was greater than 0.8.
The cognitive function of participants was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS, Form A) [22], which consists of 12 subtests that are used to calculate five age-adjusted index scores and a total score. The test indices include Immediate Memory (comprised of List Learning and Story Memory tasks), Visuospatial/Constructional (comprised of Figure Copy and Line Orientation tasks), Language (comprised of Picture Naming and Semantic Fluency tasks), Attention (comprised of Digit Span and Coding tasks), and Delayed Memory (comprised of List Recall, Story Recall, Figure Recall, and List Recognition tasks).

Assessment of metabolic indexes

Body mass index (BMI) (kg/m2) was calculated by dividing weight (kg) by height (m) squared. A trained research nurse measured blood pressure and waist circumference. After an overnight fast, blood samples were collected between 7:00 and 9:00 AM on an empty stomach. Serum fasting blood glucose (FBS), triglycerides (TG), and high-density lipoprotein cholesterol (HDLC) levels were measured by technicians who were blind to the diagnostic status of subjects.

Criteria of metabolic risk factors

Metabolic risk factors were defined using the following criteria: 1) Abdominal obesity: a waist circumference ≥90 cm in Chinese men and ≥80 cm in Chinese women; 2) Dyslipidemia: TG ≥1.7 mmol/L, or use of any lipid-lowering drugs; 3) Dyslipidemia: HDLC <1.03 mmol/L in men and <1.29 mmol/L in women, or use of any lipid-lowering drugs; 4) Hypertension: systolic blood pressure (SBP) ≥130 mm Hg or diastolic BP (DBP) ≥85 mm Hg, or treatment for hypertension; and 5) Hyperglycemia: FBS ≥5.6 mmol/L, or use of any antidiabetic medications. Subjects satisfying any three of the above correspond with the definition of MetS.

Statistical analysis

Kolmogorov-Smirnov one-sample test was used to detect the normal distribution of variables. Student’s t-test and analysis of variance (ANOVA) were performed on continuous variables, chi-square test or Fisher’s exact test for categorical variables. A 2×2 ANOVA (diagnosis×sex) was performed to assess the main effects of diagnosis and sex, as well as their interaction on demographic variables. Using education and BMI as the covariates, 2×2 analysis of covariance (ANCOVA) (diagnosis×sex) were used to explore whether the sex difference in cognitive scores would vary between patients and controls, taking the five RBANS subset score and total score as the dependent variable, respectively, and diagnosis and sex as fixed factors. After adjusting for duration of illness and BMI as covariates, logistic regression was used to compare the sex difference in the rate of metabolic risk factors and MetS in patients.
The multiple linear regression analyses investigate the association of metabolic risk factors and MetS with cognitive performances separately in male and female patients. The RBANS total and subscale scores served as the dependent variables. As covariates, age, education level, PANSS negative score, and BMI were included in the multiple linear regression analyses. Multiple comparison correction was applied using a false discovery rate. The results were presented with corrections for multiple testing. All statistical analyses were performed in IBM SPSS (version 26.0; IBM Corp., Armonk, NY, USA). Statistical significance was defined as p<0.05 (two-tailed test).


Sex differences in demographic, clinical variables, and cognitive performance in patients and healthy controls

As shown in Table 1, 358 schizophrenic patients (244 males and 114 females) and 231 healthy controls (111 males and 120 females) were recruited. The duration of illness for patients was 190.55±144.88 months. No significant difference in age was found between the two groups (schizophrenia: 40.59± 13.10 years vs. controls: 39.40±13.50 years). There were significant main effects of diagnosis with regard to education and BMI (all p<0.05). Schizophrenic patients had lower education levels and higher levels of BMI than controls. There were no significant differences in age and education levels between males and females in patients or the controls (all p> 0.05). Table 2 showed that male patients had a longer duration of illness than females (208.19±146.23 months vs. 152.90± 135.07 months, t=3.26, p=0.001) (Table 2). No significant sex difference was found in the age of onset, antipsychotic treatment, and PANSS scores (all p>0.05) (Table 2).
After controlling for education and BMI, 2×2 ANCOVA showed significant main effects of diagnosis in RBANS total and 5-subscale scores, which were all significantly lower in schizophrenic patients compared to healthy controls (all p< 0.001) (Table 1). There were no significant interactive effects of diagnosis×sex on any score were found (all p>0.05) (Table 1). Further subgroup analyses showed no significant sex differences in any cognitive score no matter in patients or controls (all p>0.05).

Sex differences in metabolic index levels and rates of metabolic risk factors

As shown in Table 2, male patients had significantly higher levels of waist circumference, SBP, DBP, and lower levels of HDLC (all p<0.05). Taking duration of illness and BMI as covariates, the logistic regression showed that the rate of abdominal obesity was lower in male patients (odds ratio [OR]=0.35, 95% confidence interval [CI]=0.17-0.71; χ2=8.36, df=1, p=0.004) (Table 3) than that in female patients. The rate of hypertension in male patients was significantly higher than that in female patients (OR=2.53, 95% CI=1.43-4.48; χ2=10.20, df=1, p=0.001) (Table 3). There was no significant sex difference in the rates of hyperglycemia, dyslipidemia, and MetS among patients (all p>0.05).

Sex difference in the association of metabolic risk factors with cognitive performances in patients

As shown in Table 4, we found dyslipidemia was negatively associated with the total score (β=-0.195, p=0.017), subscales of language (β=-0.199, p=0.017, pFDR=0.043), attention (β=-0.191, p=0.028, pFDR=0.047), and delayed memory (β=-0.243, p=0.007, pFDR=0.035) in female patients. In male patients, hyperglycemia was significantly associated with the subscales of immediate memory (β=-0.204, p=0.002, pFDR=0.010). Abdominal obesity, hypertension, and MetS were not significantly associated with cognitive function in male or female patients.
Considering the correlations among these metabolic risk factors, we further performed the multivariate regression analysis. After controlling for the other three metabolic risk factors, hyperglycemia was still significantly correlated with immediate memory score in male patients with schizophrenia (β=-0.230, p=0.001) (Supplementary Table 1 in the online-only Data Supplement). Similarly, dyslipidemia was still significantly associated with the total cognitive score (β=-0.286, p=0.002), and subscales of language (β=-0.196, p=0.029), attention (β=-0.223, p=0.024), and delayed memory (β=-0.328, p=0.002) in female patients with schizophrenia (Supplementary Table 2 in the online-only Data Supplement).
After controlling for the duration of illness, 2×2 ANCOVA showed significant interactive effects of dyslipidemia×sex on total scores (F=4.51, p=0.034) and aspects of cognitive performance including language (F=7.52, p=0.006) and attention (F=4.09, p=0.044) in patients with schizophrenia. Furthermore, we compared the cognitive scores of the non-dyslipidemia group with the dyslipidemia group by sex. In female patients, patients with dyslipidemia had significantly lower RBANS total scores (t=2.76, p=0.007) and aspects of cognitive performance including language (t=2.70, p=0.008), attention (t=2.79, p=0.006), and delayed memory (t=2.26, p=0.026) (Figure 1). However, no significant difference was found in RBANS total scores and all aspects of cognitive performance between the dyslipidemia and non-dyslipidemia group in male patients (all p>0.05) (Figure 1). In addition, after controlling for the duration of illness, the interactive effect of hyperglycemia×sex on immediate memory was not statistically significant (F=2.66, p=0.104). Further subgroup analyses showed that the hyperglycemia group had lower immediate memory than the non-hyperglycemia group in male schizophrenic patients (t=3.39, p=0.001) (Figure 1).
Within the healthy group, no significant associations of metabolic risk factors with cognitive scores were found for either men (all p>0.05) (Supplementary Table 3 in the online-only Data Supplement) or women (all p>0.05) (Supplementary Table 4 in the online-only Data Supplement).


Our study revealed significant sex differences in the rate of abdominal obesity and hypertension. Specifically, we revealed a higher rate of abdominal obesity and a lower rate of hypertension among female patients compared to their male counterparts. Additionally, our findings suggest that sex may influence the relationship between metabolic disorders and cognitive function in schizophrenia. Specifically, the analysis revealed that hyperglycemia emerged as a major risk factor for cognitive impairment in male patients, whereas dyslipidemia emerged as the primary risk factor for cognitive dysfunction in female patients.
Our study supports previous findings that patients with schizophrenia exhibit significant cognitive impairment compared to healthy controls [23]. However, we did not observe any sex differences in the degree of cognitive impairment in patients, which is consistent with the results reported by Zanelli et al. [24] and Kao et al. [25] Actually, although many studies relying on neuropsychological battery [17,26-29] and neuroimaging [30-32] have examined the impact of sex on cognitive function in schizophrenia, the conclusion remains controversial. These inconsistencies may be attributed to differences in symptomatology, medication status, illness onset, and illness duration between studies. In addition, the effect of sex on neurocognitive function in schizophrenic patients may be affected by the differences in sex hormones levels of participants when recruited, such as the different menstrual cycle stage of the woman and the reproductive stage of both sexes.
We found female patients had a higher rate of abdominal obesity than male patients. The higher rate of abdominal obesity in female patients was also reported in the previous studies [33,34]. Sex difference in the rate of abdominal obesity may attribute to the differences in the pharmacokinetics and pharmacodynamics of antipsychotic drugs between males and females [33]. Females are reported to have slower rates of drug absorption, metabolism, and excretion and have higher dopamine sensitivity than males [35,36], which may make female patients more vulnerable to weight gain and abdominal obesity, for the reason that antipsychotics lead to increased appetite and food intake through antagonistic effect on several neurotransmitter systems [37]. On the other hand, sex difference in the rate of hypertension in patients may attribute to the differences in blood pressure regulatory mechanisms between males and females [38,39], including the differences in the adrenergic receptors, reninangiotensin system (RAS), oxidative stress, nitric oxide bioavailability, and immune cells. For example, previous studies suggested that mRNA expression of renal α2B-adrenergic receptor in male spontaneously hypertensive rats is two times higher compared with females, which could contribute to higher blood pressure levels in males. In addition, males have greater expression of classical RAS components (mainly constrictor) than females, while non-classical RAS (mainly dilator) is enhanced in females.
Our study found that the metabolic risk factors of cognitive function differed from male to female patients. In male patients, hyperglycemia was associated with a worse immediate memory index score. Dyslipidemia was associated with worse language, attention, delayed memory index scores, and total score in female patients. The multivariate analyses further demonstrated that there are independent effects of hyperglycemia in males and dyslipidemia in females on cognitive ability. Zhuo et al. [40] also found that dyslipidemia is a risk factor for cognitive function in female patients with schizophrenia. A few studies have examined associations between metabolic risk factors and neurocognitive function in schizophrenia by sex. The study by Bosia et al. [41] showed that MetS was only closely related to executive function in female patients with schizophrenia. One study indicated that BMI was only correlated with male patients’ cognitive functions, including language, visuospatial skill, and attention [27]. Although not consistent with our findings, these studies demonstrate the association between metabolic risk factors and cognitive function in schizophrenia may be sex-specific. Some factors may contribute to the sex-specific association between metabolic abnormalities and cognitive function in schizophrenia. The following are the possible explanations.
Firstly, patients included in our study have a diverse history of antipsychotic treatment. Some studies have reported the effects of antipsychotic medications on cognitive function [42]. Metabolic abnormalities induced by antipsychotic drugs have also been widely reported in previous studies [43]. On the other hand, studies demonstrated the sex differences in antipsychotic treatment [44,45]. Almost all antipsychotic meditations work through the dopaminergic blockade, and the dopaminergic system is sexually dimorphic [46]. Although we compared the type of antipsychotic medication currently used between male and female patients, and there is no significant difference, it is difficult for us to evaluate the influence of antipsychotic medication previously used. Therefore, antipsychotic drug use may be one of the reasons that contribute to sex-differentiated associations of metabolic abnormalities with cognitive function in schizophrenia.
Secondly, sex hormones may also contribute to the sex-specific association between metabolic risk factors and cognitive function in schizophrenia. Sex steroid hormones are significantly associated with metabolism regulation [47]. Studies in mice have shown that estrogen depletion results in excess body fat and insulin resistance, and estrogen replacement treatment can protect estrogen-deficient mice from metabolic disease. The menopause transition induces a series of metabolic disturbances, such as obesity, glucose intolerance, and increased appetite [48,49]. On the other hand, it is reported that estrogen benefits cognitive function. Researchers found that estrogen supplementation in mice significantly enhanced their performances in cognitive tests, such as reinforcement alternation in the T-maze and working memory performance in the eightarm radial maze [50,51]. Women experience a range of cognitive changes during perimenopause, including reduced processing speed and verbal memory [52]. Atherosclerosis is one of the main mechanisms that metabolic disorders cause cognitive impairment [4]. It is reported that sex hormones are involved in the process of atherosclerosis. Estrogens and testosterones are proven to benefit lipid metabolism and have an anti-inflammatory effect, such as decreasing plaque formation and repressing the expression of tumor necrosis factor α, interleukin (IL)-1, and IL-6,53 which could slow down the process of atherosclerosis. In summary, sex-specific associations between metabolic risk factors and cognitive function in schizophrenia may be related to the hormonal status of patients. However, the underlying mechanisms of sex-specific effects of certain metabolic risk factors on the specific domain of cognitive functions need further investigation in the future.
There were some limitations to our research. Firstly, our study is a cross-sectional study, so the cause-effect relationship between metabolic disorders and cognitive performances in schizophrenia needs to be investigated further in prospective studies. Secondly, additional studies on the effects of sex hormones, such as estrogen, testosterone, and progesterone, on metabolism and cognitive function may help deepen our understanding of the mechanism involved. In addition, we did not have a drug-naïve group, which may make us more cautious when interpreting the results.
Taken together, our study suggests that sex should be considered when evaluating the impact of metabolic disorders on cognitive function in schizophrenia patients. This consideration may help to provide more precise preventative and treatment strategies for the management of cognitive deficits. Few studies take sex into account when exploring the association of metabolic disorders and cognitive deficits in schizophrenia. Our study provides some clues for further investigation in a larger cohort.

Supplementary Materials

The online-only Data Supplement is available with this article at
Supplementary Table 1.
Multi-variable linear regression of cognitive test scores in male schizophrenic patients
Supplementary Table 2.
Multi-variable linear regression of cognitive test scores in female schizophrenic patients
Supplementary Table 3.
Multi-variable linear regression of cognitive test scores in male controls
Supplementary Table 4.
Multi-variable linear regression of cognitive test scores in female controls


Availability of Data and Material

The data that support the findings of this study are available from the corresponding author Donghong Cui upon reasonable request.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Ting Xue, Donghong Cui. Data curation: Hongna Huang, Yuan Shi, Xi Chen, Lijun Wang. Formal analysis: Hongna Huang. Funding acquisition: Donghong Cui. Investigation: Hongna Huang, Yuan Shi, Zifan Xiao, Xi Chen, Lijun Wang, Zezhi Li, Ting Xue. Methodology: Hongna Huang, Lizhao Du, Zhengping Pu, Shun Yao, Zezhi Li, Ting Xue, Donghong Cui. Project administration: Donghong Cui. Resources: Donghong Cui. Software: Hongna Huang. Supervision: Ting Xue, Donghong Cui. Validation: Donghong Cui. Visualization: Hongna Huang, Ting Xue, Donghong Cui. Writing—original draft: Hongna Huang, Lizhao Du, Zhengping Pu, Zifan Xiao. Writing—review & editing: Ting Xue, Donghong Cui.

Funding Statement

We would like to express our sincere gratitude to the patients and healthy controls who participated in this research. This work was supported by the National Key R&D Program of China (2017YFC0909200) and the National Natural Science Foundation of China (81671336, 82271544).

Figure 1.
Sex differences in the association of dyslipidemia and hyperglycemia with cognitive performances in schizophrenia. A and B: Patients with dyslipidemia exhibited worse RBANS language, attention, delayed memory, and total score compared with non-dyslipidemia only in females (all p<0.05). C and D: Patients with hyperglycemia had lower immediate memory than non-hyperglycemia patients, and the results only appeared in male patients (p=0.001). *p<0.05; **p<0.01. RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.
Table 1.
Demographic information and clinical characteristics of sex subgroups among schizophrenic patients (SZ) and healthy controls (HC)
SZ (N=358)
HC (N=231)
Male (N=244) Female (N=114) Male (N=111) Female (N=120) F (p) F (p) F (p)
Age (yr) 41.42±13.18 38.81±12.81 38.99±13.34 39.78±13.68 0.40 (0.528) 0.63 (0.429) 2.19 (0.139)
Education (yr) 10.70±3.49 10.79±4.30 14.64±4.15 14.76±4.65 121.88 (<0.001)*** 0.09 (0.770) 0.001 (0.973)
BMI (kg/m2) 24.42±3.67 23.87±4.42 23.23±2.37 21.59±2.26 34.53 (<0.001)*** 13.91 (< 0.001)*** 3.42 (0.065)
 Immediate memory 65.20±21.21 68.41±21.01 81.75±16.93 81.34±19.54 19.69 (<0.001)*** 0.87 (0.353) 1.03 (0.311)
 Visuospatial skill 86.43±21.83 83.72±21.15 101.25±14.33 99.21±12.93 26.96 (<0.001)*** 1.45 (0.229) 0.17 (0.684)
 Language 75.97±15.52 72.58±21.62 92.39±14.71 89.50±17.61 41.44 (<0.001)*** 4.70 (0.031)* 0.06 (0.805)
 Attention 82.84±22.97 84.52±26.31 110.86±14.51 112.34±16.77 100.03 (<0.001)*** 1.17 (0.280) <0.001 (0.982)
 Delayed memory 63.96±19.72 67.94±22.03 88.60±16.28 91.86±15.16 108.80 (<0.001)*** 7.27 (0.007)* 0.004 (0.947)
 Total score 69.07±16.48 70.75±18.76 92.40±13.42 92.98±16.13 116.02 (<0.001)*** 1.22 (0.270) 0.11 (0.737)

Values are presented as mean±standard deviation. The p-values for RBANS were adjusted for education and BMI as covariates.

* significant at p<0.05;

*** significant at p<0.001.

BMI, body mass index; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status

Table 2.
Demographic characteristics and clinical variables of male and female schizophrenic patients
Male (N=244) Female (N=114) t/χ2 p
Age of onset (yr) 24.66±7.91 26.40±9.45 -1.74 0.082
Duration of illness (mo) 208.19±146.23 152.90±135.07 3.26 0.001**
Antipsychotic drugs 5.27 0.071
 Typical 14 (5.7) 1 (0.9)
 Atypical 201 (82.4) 103 (90.4)
 Atypical+typical 18 (7.4) 7 (6.1)
PANSS score
 Positive symptom 16.45±7.94 17.89±10.95 -1.25 0.211
 Negative symptom 17.29±8.03 16.39±9.90 0.84 0.401
 General psychopathology 32.83±12.77 35.33±18.43 -1.31 0.193
 Total score 66.55±25.24 69.61±36.17 -0.82 0.416
Metabolic indexes
 Waist circumference (cm) 90.83±10.25 85.75±12.51 3.49 0.001**
 Systolic BP (mm Hg) 121.41±12.40 115.72±10.46 4.23 <0.001***
 Diastolic BP (mm Hg) 77.93±8.66 74.28±6.90 3.94 <0.001***
 Fasting glucose (mmol/L) 5.25±1.16 5.22±1.72 0.17 0.863
 Triglycerides (mmol/L) 1.63±0.94 1.56±0.93 0.67 0.502
 HDLC (mmol/L) 1.10±0.28 1.34±0.34 -6.36 <0.001***

Values are presented as mean±standard deviation or number (%).

** significant at p<0.01;

*** significant at p<0.001.

PANSS, the Positive and Negative Syndrome Scale; BP, blood pressure; HDLC, high-density lipoprotein cholesterol

Table 3.
Sex difference in the prevalence of MetS and its components in schizophrenic patients
Male (N=244) Female (N=114) B Wald χ2 OR 95% CI p
Abdominal obesity 131 (58.5) 63 (66.3) -1.05 8.36 0.35 0.17-0.71 0.004**
Hypertension 99 (40.6) 24 (21.2) 0.93 10.20 2.53 1.43-4.48 0.001**
Hyperglycemia 68 (28.8) 25 (22.7) 0.04 0.02 1.04 0.58-1.86 0.894
Dyslipidemia 147 (61.0) 67 (59.8) -0.12 0.22 0.89 0.53-1.47 0.638
MetS 83 (38.1) 29 (31.9) 0.07 0.05 1.07 0.59-1.96 0.818

Values are presented as number (%). Dyslipidemia: Hypertriglyceridemia or/and hypo-HDLC. The p-values were adjusted for duration of illness and BMI as covariates.

** significant at p<0.01.

MetS, metabolic syndrome; OR, odds ratio; CI, confidence interval; HDLC, high-density lipoprotein cholesterol; BMI, body mass index

Table 4.
Association of MetS and its components with cognitive performances in schizophrenic patients stratified by sex
MetS Abdominal obesity Hypertension Hyperglycemia Dyslipidemia
Immediate memory
 Male -0.106 -0.054 0.009 -0.204* -0.008
 Female -0.128 -0.079 -0.124 0.010 0.034
Visuospatial skill
 Male 0.007 -0.014 0.005 0.059 -0.030
 Female -0.006 -0.078 0.084 -0.074 -0.092
 Male -0.022 0.050 0.020 -0.025 -0.026
 Female -0.003 0.106 0.035 -0.004 -0.199*
 Male -0.022 -0.156 0.018 0.021 -0.062
 Female -0.065 0.001 0.100 -0.018 -0.191*
Delayed memory
 Male -0.028 -0.001 -0.008 -0.080 -0.080
 Female -0.045 -0.065 0.117 -0.014 -0.243*
Total score
 Male -0.031 -0.049 0.019 -0.060 -0.054
 Female -0.063 -0.023 0.057 -0.028 -0.195*

Adjusted for age, education, PANSS negative scores, and BMI. Standardized regression coefficients are shown.

* pFDR<0.05.

MetS, metabolic syndrome; PANSS, Positive and Negative Syndrome Scale; BMI, body mass index


1. Marder SR, Cannon TD. Schizophrenia. N Engl J Med 2019;381:1753-1761.
crossref pmid
2. Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Primers 2015;1:15067
3. Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, et al. Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 2022;9:59
crossref pmid pmc pdf
4. Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. Nat Rev Cardiol 2015;12:267-277.
crossref pmid pdf
5. van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta 2009;1792:470-481.
crossref pmid
6. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011;9:48
crossref pmid pmc pdf
7. Kouvari M, D’Cunha NM, Travica N, Sergi D, Zec M, Marx W, et al. Metabolic syndrome, cognitive impairment and the role of diet: a narrative review. Nutrients 2022;14:333
crossref pmid pmc
8. Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry 2013;12:240-250.
crossref pmid pmc
9. Grover S, R P, Sahoo S, Gopal S, Nehra R, Ganesh A, et al. Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia. Psychiatry Res 2019;278:56-64.
crossref pmid
10. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010;167:1232-1239.
crossref pmid
11. Takayanagi Y, Cascella NG, Sawa A, Eaton WW. Diabetes is associated with lower global cognitive function in schizophrenia. Schizophr Res 2012;142:183-187.
crossref pmid pmc
12. Depp CA, Strassnig M, Mausbach BT, Bowie CR, Wolyniec P, Thornquist MH, et al. Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. Bipolar Disord 2014;16:422-431.
crossref pmid pmc
13. Hagi K, Nosaka T, Dickinson D, Lindenmayer JP, Lee J, Friedman J, et al. Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and metaanalysis. JAMA Psychiatry 2021;78:510-518.
crossref pmid
14. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hänninen T, Soininen H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006;67:843-847.
crossref pmid
15. Schuur M, Henneman P, van Swieten JC, Zillikens MC, de Koning I, Janssens AC, et al. Insulin-resistance and metabolic syndrome are related to executive function in women in a large family-based study. Eur J Epidemiol 2010;25:561-568.
crossref pmid pmc
16. Huo N, Vemuri P, Graff-Radford J, Syrjanen J, Machulda M, Knopman DS, et al. Sex differences in the association between midlife cardiovascular conditions or risk factors with midlife cognitive decline. Neurology 2022;98:e623-e632.
crossref pmid pmc
17. Mendrek A, Mancini-Marïe A. Sex/gender differences in the brain and cognition in schizophrenia. Neurosci Biobehav Rev 2016;67:57-78.
crossref pmid
18. Ran MS, Mao WJ, Chan CL, Chen EY, Conwell Y. Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study. Br J Psychiatry 2015;206:283-288.
crossref pmid pmc
19. Dong R, Zhao NO, Wu HE, Yu L, Zhang XY. Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics. J Psychiatr Res 2021;138:492-499.
crossref pmid
20. Goldstein JM, Seidman LJ, Goodman JM, Koren D, Lee H, Weintraub S, et al. Are there sex differences in neuropsychological functions among patients with schizophrenia? Am J Psychiatry 1998;155:1358-1364.
crossref pmid
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
crossref pmid
22. Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-319.
crossref pmid
23. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013;70:1107-1112.
crossref pmid
24. Zanelli J, Morgan K, Dazzan P, Morgan C, Russo M, Pilecka I, et al. Gender differences in neuropsychological performance across psychotic disorders--a multi-centre population based case-control study. PLoS One 2013;8:e77318.
crossref pmid pmc
25. Kao YC, Liu YP, Lien YJ, Lin SJ, Lu CW, Wang TS, et al. The influence of sex on cognitive insight and neurocognitive functioning in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013;44:193-200.
crossref pmid
26. Pu C, Qiu Y, Zhou T, Yang F, Lu Z, Wang C, et al. Gender differences of neurocognitive functioning in patients with first-episode schizophrenia in China. Compr Psychiatry 2019;95:152132
crossref pmid
27. Wei CW, Chen YQ, Ma M, Xiu MH, Zhang XY. Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia. Transl Psychiatry 2020;10:18
crossref pmid pmc pdf
28. Li W, Lin S, Yue L, Fang Y, Xiao S. Sex differences in obesity and cognitive function in Chinese elderly patients with chronic schizophrenia. Front Endocrinol (Lausanne) 2022;13:742474
crossref pmid pmc
29. Collinson SL, Mackay CE, James AC, Quested DJ, Phillips T, Roberts N, et al. Brain volume, asymmetry and intellectual impairment in relation to sex in early-onset schizophrenia. Br J Psychiatry 2003;183:114-120.
crossref pmid
30. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 2013;39:1129-1138.
crossref pmid
31. Türközer HB, Lizano P, Adhan I, Ivleva EI, Lutz O, Zeng V, et al. Regional and sex-specific alterations in the visual cortex of individuals with psychosis spectrum disorders. Biol Psychiatry 2022;92:396-406.
crossref pmid
32. Lauriello J, Hoff A, Wieneke MH, Blankfeld H, Faustman WO, Rosenbloom M, et al. Similar extent of brain dysmorphology in severely ill women and men with schizophrenia. Am J Psychiatry 1997;154:819-825.
crossref pmid
33. Seeman MV. Men and women respond differently to antipsychotic drugs. Neuropharmacology 2020;163:107631
crossref pmid
34. Bener A, Al-Hamaq AO, Dafeeah EE. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Metab Syndr 2014;8:24-29.
crossref pmid
35. Chen KC, Yang YK, Howes O, Lee IH, Landau S, Yeh TL, et al. Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysis. Schizophr Bull 2013;39:378-386.
crossref pmid
36. Brand BA, Haveman YRA, de Beer F, de Boer JN, Dazzan P, Sommer IEC. Antipsychotic medication for women with schizophrenia spectrum disorders. Psychol Med 2022;52:649-663.
crossref pmid
37. Henderson DC, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015;2:452-464.
crossref pmid
38. Elmarakby AA, Sullivan JC. Sex differences in hypertension: lessons from spontaneously hypertensive rats (SHR). Clin Sci (Lond) 2021;135:1791-1804.
crossref pmid pmc pdf
39. Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol 2018;14:185-201.
crossref pmid pdf
40. Zhuo C, Liu W, Jiang R, Li R, Yu H, Chen G, et al. Metabolic risk factors of cognitive impairment in young women with major psychiatric disorder. Front Psychiatry 2022;13:880031
crossref pmid pmc
41. Bosia M, Spangaro M, Sapienza J, Martini F, Civardi S, Buonocore M, et al. Cognition in schizophrenia: modeling the interplay between interleukin-1β C-511T polymorphism, metabolic syndrome, and sex. Neuropsychobiology 2021;80:321-332.
crossref pmid pdf
42. Rubin LH, Haas GL, Keshavan MS, Sweeney JA, Maki PM. Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia. Neuropsychopharmacology 2008;33:290-297.
crossref pmid pdf
43. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020;7:64-77.
crossref pmid pmc
44. Fernando P, Sommer IEC, Hasan A. Do we need sex-oriented clinical practice guidelines for the treatment of schizophrenia? Curr Opin Psychiatry 2020;33:192-199.
crossref pmid
45. Seeman MV. Sex differences in schizophrenia relevant to clinical care. Expert Rev Neurother 2021;21:443-453.
crossref pmid
46. Semaan SJ, Kauffman AS. Sexual differentiation and development of forebrain reproductive circuits. Curr Opin Neurobiol 2010;20:424-431.
crossref pmid pmc
47. Varlamov O. Western-style diet, sex steroids and metabolism. Biochim Biophys Acta Mol Basis Dis 2017;1863:1147-1155.
crossref pmid
48. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause - global prevalence, physiology and implications. Nat Rev Endocrinol 2018;14:199-215.
crossref pmid pdf
49. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. Biomed Res Int 2014;2014:757461
crossref pmid pmc pdf
50. Fader AJ, Hendricson AW, Dohanich GP. Estrogen improves performance of reinforced T-maze alternation and prevents the amnestic effects of scopolamine administered systemically or intrahippocampally. Neurobiol Learn Mem 1998;69:225-240.
crossref pmid
51. Bimonte HA, Denenberg VH. Estradiol facilitates performance as working memory load increases. Psychoneuroendocrinology 1999;24:161-173.
crossref pmid
52. Lamar M, Resnick SM, Zonderman AB. Longitudinal changes in verbal memory in older adults: distinguishing the effects of age from repeat testing. Neurology 2003;60:82-86.
crossref pmid
53. Vaura F, Palmu J, Aittokallio J, Kauko A, Niiranen T. Genetic, molecular, and cellular determinants of sex-specific cardiovascular traits. Circ Res 2022;130:611-631.
crossref pmid


Browse all articles >

Editorial Office
#522, 27, Seochojungang-ro 24-gil, Seocho-gu, Seoul 06601, Korea
Tel: +82-2-717-0892    E-mail:                

Copyright © 2023 by Korean Neuropsychiatric Association.

Developed in M2PI

Close layer
prev next